![Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic. - ScienceDirect Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic. - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1359644620305092-gr1.jpg)
Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic. - ScienceDirect
![Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals | BMJ Open Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals | BMJ Open](https://bmjopen.bmj.com/content/bmjopen/12/1/e052186/F2.large.jpg)
Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals | BMJ Open
![Marinus Launches Expanded Access Program for Ganaxolone Treatment in CDKL5 Deficiency Disorder - CDKL5 UK Marinus Launches Expanded Access Program for Ganaxolone Treatment in CDKL5 Deficiency Disorder - CDKL5 UK](https://curecdkl5.org.uk/wp-content/uploads/2020/12/Marinus.png)
Marinus Launches Expanded Access Program for Ganaxolone Treatment in CDKL5 Deficiency Disorder - CDKL5 UK
![CTD Holdings Announces FDA Approval of US Expanded Access Treatment Program in Niemann-Pick Disease Type C - NPUK CTD Holdings Announces FDA Approval of US Expanded Access Treatment Program in Niemann-Pick Disease Type C - NPUK](https://www.npuk.org/wp-content/uploads/2016/08/npuk-logo-white.png)
CTD Holdings Announces FDA Approval of US Expanded Access Treatment Program in Niemann-Pick Disease Type C - NPUK
![PPT - The Safety of Tenofovir DF for the Treatment of HIV Infection: The First 4 Years PowerPoint Presentation - ID:904627 PPT - The Safety of Tenofovir DF for the Treatment of HIV Infection: The First 4 Years PowerPoint Presentation - ID:904627](https://image.slideserve.com/904627/the-safety-of-tenofovir-df-for-the-treatment-of-hiv-infection-the-first-4-years-l.jpg)
PPT - The Safety of Tenofovir DF for the Treatment of HIV Infection: The First 4 Years PowerPoint Presentation - ID:904627
![Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals | BMJ Open Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals | BMJ Open](https://bmjopen.bmj.com/content/bmjopen/12/1/e052186/F1.large.jpg)
Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals | BMJ Open
![Initiating Early Access Programs: 5 Things to Consider :: executive insight | healthcare consultants Initiating Early Access Programs: 5 Things to Consider :: executive insight | healthcare consultants](https://www.executiveinsight.ch/application/files/thumbnails/image_sm/5715/2104/1179/initiatingearly_img1.png)